Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to ...

Leading doctors answer common questions about infertility, from early warning signs and lifestyle habits to medical ...

A lot of good can come when celebrities speak out about their medical diagnoses. However, these celebs say they initially ...

In 1885, Gilles de la Tourette, a young trainee in neurology, was asked to bring clarity to movement disorders and described ...

For Dr. Debra Rouse, mettafemina is the era for women to love themselves first, instead of framing it as a tumultuous time.

Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE PipelineNANJING, China, Oct. (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, Stock ...

ATG-022 (Claudin 18.2 Antibody-Drug Conjugate) Title: ATG-022, a Claudin 18.2 ADC, in Advanced Gastric and Gastroesophageal Junction Cancer (CLINCH): Phase 2 Results Poster Number: 2886P Date: October ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the ...

Friendly An anti-Hu antibody positive result raises concern for a cancer-associated neurological immune response, especially ...

The hospital system told families in August that it plans to close its PANDAS/PANS treatment program in January.

Xencor chose an XmAb819 dose after five of 11 patients responded; severe treatment-related events affected 72.1 per cent ...

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in ...